379 related articles for article (PubMed ID: 27474089)
1. Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis.
O'Dwyer DN; Ashley SL; Moore BB
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L590-601. PubMed ID: 27474089
[TBL] [Abstract][Full Text] [Related]
2. Inflammation and immunity in IPF pathogenesis and treatment.
Heukels P; Moor CC; von der Thüsen JH; Wijsenbeek MS; Kool M
Respir Med; 2019 Feb; 147():79-91. PubMed ID: 30704705
[TBL] [Abstract][Full Text] [Related]
3. IL-37 Attenuates Lung Fibrosis by Inducing Autophagy and Regulating TGF-β1 Production in Mice.
Kim MS; Baek AR; Lee JH; Jang AS; Kim DJ; Chin SS; Park SW
J Immunol; 2019 Oct; 203(8):2265-2275. PubMed ID: 31519861
[TBL] [Abstract][Full Text] [Related]
4. A Tale of Two Proteolytic Machines: Matrix Metalloproteinases and the Ubiquitin-Proteasome System in Pulmonary Fibrosis.
Roque W; Boni A; Martinez-Manzano J; Romero F
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485920
[TBL] [Abstract][Full Text] [Related]
5. Reduced FoxO3a expression causes low autophagy in idiopathic pulmonary fibrosis fibroblasts on collagen matrices.
Im J; Hergert P; Nho RS
Am J Physiol Lung Cell Mol Physiol; 2015 Sep; 309(6):L552-61. PubMed ID: 26186945
[TBL] [Abstract][Full Text] [Related]
6. Lung Fibroblasts, Aging, and Idiopathic Pulmonary Fibrosis.
Pardo A; Selman M
Ann Am Thorac Soc; 2016 Dec; 13 Suppl 5():S417-S421. PubMed ID: 28005427
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 regulation of fibroblast activation in pulmonary fibrosis.
Sontake V; Wang Y; Kasam RK; Sinner D; Reddy GB; Naren AP; McCormack FX; White ES; Jegga AG; Madala SK
JCI Insight; 2017 Feb; 2(4):e91454. PubMed ID: 28239659
[TBL] [Abstract][Full Text] [Related]
9. Autophagy, an important therapeutic target for pulmonary fibrosis diseases.
Zhao H; Wang Y; Qiu T; Liu W; Yao P
Clin Chim Acta; 2020 Mar; 502():139-147. PubMed ID: 31877297
[TBL] [Abstract][Full Text] [Related]
10. tPA promotes the proliferation of lung fibroblasts and activates the Wnt/β-catenin signaling pathway in idiopathic pulmonary fibrosis.
Chen L; Hou J; Fu X; Chen X; Wu J; Han X
Cell Cycle; 2019 Nov; 18(22):3137-3146. PubMed ID: 31550972
[TBL] [Abstract][Full Text] [Related]
11. Autophagy and the unfolded protein response promote profibrotic effects of TGF-β
Ghavami S; Yeganeh B; Zeki AA; Shojaei S; Kenyon NJ; Ott S; Samali A; Patterson J; Alizadeh J; Moghadam AR; Dixon IMC; Unruh H; Knight DA; Post M; Klonisch T; Halayko AJ
Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L493-L504. PubMed ID: 29074489
[TBL] [Abstract][Full Text] [Related]
12. Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis?
Kosanovic D; Dahal BK; Wygrecka M; Reiss I; Günther A; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Schermuly RT; Banat GA
Histol Histopathol; 2013 Jun; 28(6):691-9. PubMed ID: 23436625
[TBL] [Abstract][Full Text] [Related]
13. S100a4 Is Secreted by Alternatively Activated Alveolar Macrophages and Promotes Activation of Lung Fibroblasts in Pulmonary Fibrosis.
Zhang W; Ohno S; Steer B; Klee S; Staab-Weijnitz CA; Wagner D; Lehmann M; Stoeger T; Königshoff M; Adler H
Front Immunol; 2018; 9():1216. PubMed ID: 29910813
[TBL] [Abstract][Full Text] [Related]
14. Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis.
Tiwari P; Verma S; Washimkar KR; Nilakanth Mugale M
Int Immunopharmacol; 2024 Jun; 135():112269. PubMed ID: 38781610
[TBL] [Abstract][Full Text] [Related]
15. Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis.
Mora AL; Bueno M; Rojas M
J Clin Invest; 2017 Feb; 127(2):405-414. PubMed ID: 28145905
[TBL] [Abstract][Full Text] [Related]
16. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis.
Pardo A; Cabrera S; Maldonado M; Selman M
Respir Res; 2016 Mar; 17():23. PubMed ID: 26944412
[TBL] [Abstract][Full Text] [Related]
17. Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the 'bed' that counts and not 'the sleepers'.
Tomos IP; Tzouvelekis A; Aidinis V; Manali ED; Bouros E; Bouros D; Papiris SA
Expert Rev Respir Med; 2017 Apr; 11(4):299-309. PubMed ID: 28274188
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.
Craig VJ; Zhang L; Hagood JS; Owen CA
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):585-600. PubMed ID: 26121236
[TBL] [Abstract][Full Text] [Related]
19. Nanoengineered immunosuppressive therapeutics modulating M1/M2 macrophages into the balanced status for enhanced idiopathic pulmonary fibrosis therapy.
Chang X; Xing L; Wang Y; Zhou TJ; Shen LJ; Jiang HL
Nanoscale; 2020 Apr; 12(16):8664-8678. PubMed ID: 32227023
[TBL] [Abstract][Full Text] [Related]
20. [Immunopathogenesis of idiopathic pulmonary fibrosis].
Demkow U
Pneumonol Alergol Pol; 2014; 82(1):55-60. PubMed ID: 24391072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
